Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 234

Sort by

Sort Order Select

Journal Articles

A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)

John O. Mascarenhas, Uma Borate, Prithviraj Bose, John C. Byrd, Jacqueline S. Garcia, Michael R. Grunwald, Gabriela S. Hobbs, Ronald Hoffman, Andrew T. Kuykendall, Ruben A. Mesa, Stephen Oh, Raajit Rampal, Abdulraheem Yacoub, David P. Steensma

Blood (2024) 144 (Supplement 1): 3147.1.

https://doi.org/10.1182/blood-2024-193905

Published: 2024

Journal Articles

KT-253, a Highly Potent and Selective MDM2 Protein Degrader, Eliminates Malignant Myelofibrosis Stem/Progenitor Cells

Min Lu, Lijuan Xia, Yogesh Chutake, Joyoti Dey, Ronald Hoffman

Blood (2024) 144 (Supplement 1): 3588.

https://doi.org/10.1182/blood-2024-210354

Published: 2024

Journal Articles

TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2 V617F Mutant Mice

Maayan Levy, Huihui Li, Andrew Dunbar, Zixing Huang, Young Park, Min Lu, Pinanong Na Phattalung, Marina Planoutene, Carla Casu, Stefano Rivella, Shuling Guo, Ross L Levine, Ronald Hoffman, Yelena Ginzburg

Blood (2024) 144 (Supplement 1): 8.

https://doi.org/10.1182/blood-2024-203806

Published: 2024

Journal Articles

Gut Microbiota Promote Chronic Inflammation in Jak2 V617F Mice

Hui Hui Li, Althea Agdamag, Zixing Huang, Anisa A. Gumerova, Georgii Pevnev, Paul S. Frenette, Mone Zaidi, Jeffrey A. Glassberg, Yelena Ginzburg, Ronald Hoffman

Blood (2024) 144 (Supplement 1): 2660.

https://doi.org/10.1182/blood-2024-198221

Published: 2024

Journal Articles

Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)

Marina Kremyanskaya, Ronald Hoffman, Lee Ping Chew, Azizan Sharif, Boyan Semov, Ahlam Naila Kori, Hanlon Sia, Carolyn S. Grove, Ashley P Ng, Akash Kalro, Indu Raman, Ganesh Kasinathan, Olubunmi Oduwole, Monica Gomez-Palou, Henry Fok, Steve Romano, Curtis Rambaran, Alberto Martinez

Blood (2024) 144 (Supplement 1): 656.

https://doi.org/10.1182/blood-2024-205854

Published: 2024

Journal Articles

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 6629.

https://doi.org/10.1182/blood-2024-200268

Published: 2024

Journal Articles

Selinexor Depletes Ruxolitinib Refractory Myelofibrosis Hematopoietic Stem Cells By Inducing Apoptosis and Blunting the Pro-Inflammatory Milieu

Min Lu, MD Babu Mia, Lijuan Xia, Andrea Ellero, Christopher J. Walker, Ronald Hoffman

Blood (2024) 144 (Supplement 1): 1377.

https://doi.org/10.1182/blood-2024-205114

Published: 2024

Journal Articles

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 243.

https://doi.org/10.1182/blood-2024-206688

Published: 2024

Journal Articles

Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells

Cara Clementelli, MD Babu Mia, Sarah Haines, Christoph Schaniel, Malgorzata Olszewska, Joann Arandela, Sebastian Elghaity-beckley, Sophie Klingborg, Zinedine Hoque, Min Lu, Eirini Papapetrou, Ronald Hoffman, Bridget Kelly Marcellino

Blood (2024) 144 (Supplement 1): 873.

https://doi.org/10.1182/blood-2024-204136

Published: 2024

Journal Articles

High-Resolution Chromosomal Microarrays Reveals Exon-Level Deletion in Chromosome 12q14.3 in Patients with Myeloproliferative Neoplasms

Joseph Tripodi, Shivani Handa, Christoph Schaniel, Daiva Ahire, Ronald Hoffman, Vesna Najfeld

Blood (2024) 144 (Supplement 1): 4520.

https://doi.org/10.1182/blood-2024-206440

Published: 2024

Journal Articles

Role of HMGA2 Overexpression Caused By Specific Genetic HMGA2 Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients

Christoph Schaniel, Shivani Handa, Joseph Tripodi, MD Babu Mia, Christian Salib, Jeff Vierstra, Allison J Cote, Daiva Ahire, Douglas Tremblay, Bridget Kelly Marcellino, John A Stamatoyannopoulos, Vesna Najfeld, Ronald Hoffman

Blood (2024) 144 (Supplement 1): 4512.

https://doi.org/10.1182/blood-2024-205834

Published: 2024

Journal Articles

Durable Clinical Benefits of Idasanutlin Therapy in Hydroxyurea-Refractory Polycythemia Vera

Julian Waksal, Ronald Hoffman, Abdulraheem Yacoub, Francesco Passamonti, Aaron T. Gerds, Vikas Gupta, Grace Van Hyfte, Jayanshu Jain, Margherita Maffioli, Natalia Rosas, John Mascarenhas

Blood (2023) 142 (Supplement 1): 3187.

https://doi.org/10.1182/blood-2023-182116

Published: 2023

Journal Articles

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Xiaoli Wang, Andrew Davis, Xiaoping Su, Muharrem Muftuoglu, Cecile Krejsa, John Mascarenhas, Michael Andreeff, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2023-187426

Published: 2023

Journal Articles

Thrombocytopenia Associated with Myelofibrosis Is Characterized By a Reduced Proportion of Megakaryocyte (MK) Biased Hematopoietic Stem Cells, Defects in MK Maturation and Increased Levels of Pro-Inflammatory Cytokines

Lilian Varricchio, Gohar Mosoyan, Sebastian Elghaity-beckley, John Mascarenhas, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 1779.

https://doi.org/10.1182/blood-2023-178087

Published: 2023

Journal Articles

A Dual-Specific Inhibitor of Rock/Aurk, RR-1752, for Primary Myelofibrosis

Liqiang Zhang, Kathryn McGinnis, Paul Gonzales, Maggie Murray, Emily Cluff, MD Babu Mia, Christoph Schaniel, Joseph Mascarenhas, Alan M Miller, Ronald Hoffman, Stephen Gately

Blood (2023) 142 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2023-182046

Published: 2023

Journal Articles

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Andrew Srisuwananukorn, Giuseppe Gaetano Loscocco, Andrew T. Kuykendall, James M Dolezal, Raffaella Santi, Ling Zhang, Avani M Singh, Paola Guglielmelli, Alessandro Maria Vannucchi, Douglas Tremblay, Alexander T Pearson, Mohamed E. Salama, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 901.

https://doi.org/10.1182/blood-2023-173877

Published: 2023

Journal Articles

Do Hematologic Parameters Predict Thrombosis or Disease Transformation in Essential Thrombocythemia?

Hannah Goulart, Dahniel L Sastow, Nicholas Dreher, Metodi Balev, Grace Van Hyfte, Marina Kremyanskaya, Ronald Hoffman, John Mascarenhas, Douglas Tremblay

Blood (2023) 142 (Supplement 1): 3200.

https://doi.org/10.1182/blood-2023-182450

Published: 2023

Journal Articles

Upregulation of Platelet Transcripts As Biomarkers of Fibrotic Progression in Myeloproliferative Neoplasms

Anitria Cotton, Ryan Collinson, Lynne Wilson, Zi Yun Ng, Hun S Chuah, Michael F. Leahy, Rebecca Howman, Carolyn Grove, Hasib Sidiqi, Malcolm Webb, Darren Boey, Olivia Ruhen, Michael Phillips, Matthew Linden, Kathy Fuller, Wendy N. Erber, Ronald Hoffman, John D. Crispino, Belinda Guo

Blood (2023) 142 (Supplement 1): 4520.

https://doi.org/10.1182/blood-2023-182140

Published: 2023

Journal Articles

Conventional Cytogenetic Analysis and Array CGH+SNP Identify Essential Thrombocythemia (ET)/Prefibrotic Primary Myelofibrosis (pre-PMF) Patients Who Are at Risk for Disease Progression

Joseph Tripodi, Ronald Hoffman, Douglas Tremblay, John Mascarenhas, Marina Kremyanskaya, Ian Novoselac, Vesna Najfeld

Blood (2023) 142 (Supplement 1): 1832.

https://doi.org/10.1182/blood-2023-181092

Published: 2023

Journal Articles

The Presence of Ring Chromosomes in Patients with Myeloid Neoplasms Is Predictive of a Poor Outcome

Daniel I. Nathan, Ronald Hoffman, Daiva Ahire, John Mascarenhas, Lewis R. Silverman, Vesna Najfeld, Jonathan Feld

Blood (2023) 142 (Supplement 1): 2940.

https://doi.org/10.1182/blood-2023-179585

Published: 2023

NARROW

KT-253, a Highly Potent and Selective MDM2 Protein Degrader, Eliminates Malignant Myelofibrosis Stem/Progenitor Cells

TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2 V617F Mutant Mice

Gut Microbiota Promote Chronic Inflammation in Jak2 V617F Mice

Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Selinexor Depletes Ruxolitinib Refractory Myelofibrosis Hematopoietic Stem Cells By Inducing Apoptosis and Blunting the Pro-Inflammatory Milieu

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells

High-Resolution Chromosomal Microarrays Reveals Exon-Level Deletion in Chromosome 12q14.3 in Patients with Myeloproliferative Neoplasms

Role of HMGA2 Overexpression Caused By Specific Genetic HMGA2 Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients

Durable Clinical Benefits of Idasanutlin Therapy in Hydroxyurea-Refractory Polycythemia Vera

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Thrombocytopenia Associated with Myelofibrosis Is Characterized By a Reduced Proportion of Megakaryocyte (MK) Biased Hematopoietic Stem Cells, Defects in MK Maturation and Increased Levels of Pro-Inflammatory Cytokines

A Dual-Specific Inhibitor of Rock/Aurk, RR-1752, for Primary Myelofibrosis

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Do Hematologic Parameters Predict Thrombosis or Disease Transformation in Essential Thrombocythemia?

Upregulation of Platelet Transcripts As Biomarkers of Fibrotic Progression in Myeloproliferative Neoplasms

Conventional Cytogenetic Analysis and Array CGH+SNP Identify Essential Thrombocythemia (ET)/Prefibrotic Primary Myelofibrosis (pre-PMF) Patients Who Are at Risk for Disease Progression

The Presence of Ring Chromosomes in Patients with Myeloid Neoplasms Is Predictive of a Poor Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only